The estimated Net Worth of Francis E Jr Odonnell is at least $11.6 Milion dollars as of 11 May 2020. Francis Odonnell owns over 22,500 units of Biodelivery Sciences International stock worth over $3,510,732 and over the last 20 years Francis sold BDSI stock worth over $8,107,984.
Francis has made over 57 trades of the Biodelivery Sciences International stock since 2004, according to the Form 4 filled with the SEC. Most recently Francis exercised 22,500 units of BDSI stock worth $125,775 on 11 May 2020.
The largest trade Francis's ever made was buying 300,000 units of Biodelivery Sciences International stock on 30 September 2005 worth over $588,000. On average, Francis trades about 34,762 units every 68 days since 2004. As of 11 May 2020 Francis still owns at least 628,038 units of Biodelivery Sciences International stock.
You can see the complete history of Francis Odonnell stock trades at the bottom of the page.
Francis's mailing address filed with the SEC is C/O BIODELIVERY SCIENCES INTL, INC.,, 4131 PARKLAKE AVENUE, SUITE 225, RALEIGH, NC, 27612.
Over the last 21 years, insiders at Biodelivery Sciences International have traded over $111,671,776 worth of Biodelivery Sciences International stock and bought 1,813,177 units worth $5,352,510 . The most active insiders traders include International, L.P. Elliott, Associates, L.P. Elliott oraz Healthcare Master Fund Ltd .... On average, Biodelivery Sciences International executives and independent directors trade stock every 18 days with the average trade being worth of $420,648. The most recent stock trade was executed by Jeffrey Allen Bailey on 9 March 2022, trading 5,333 units of BDSI stock currently worth $29,811.
BioDelivery Sciences International, Inc. is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.
Biodelivery Sciences International executives and other stock owners filed with the SEC include: